Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting

Clinical and Vaccine Immunology

Volumn 14, Issue 7, 2007, Pages 869-874

  Cassataro, Juliana ^a,b   Velikovsky, Carlos A ^b,c,e   Bruno, Laura ^b   Estein, Silvia M ^c   De La Barrera, Silvia ^d   Bowden, Raúl ^c   Fossati, Carlos A ^b   Giambartolomei, Guillermo H ^a,b  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c UNIVERSIDAD NACIONAL DEL CENTRO DE LA PROVINCIA DE BUENOS AIRES   (Argentina)

^d INST DE INVEST HEMATOLOGICAS   (Argentina)

^e UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN 31; RECOMBINANT OUTER MEMBRANE PROTEIN 31; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; BRUCELLA VACCINE; IMMUNOGLOBULIN G; OMP31 PROTEIN, BRUCELLA MELITENSIS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BRUCELLA MELITENSIS; BRUCELLA OVIS; BRUCELLOSIS; CONTROLLED STUDY; CYTOTOXICITY; DNA IMMUNIZATION; DRUG EFFICACY; DRUG POTENTIATION; ESCHERICHIA COLI; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; IMMUNIZATION; IMMUNOLOGY; MICROBIOLOGY; TH1 CELL;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BRUCELLA OVIS; BRUCELLA VACCINE; BRUCELLOSIS; FEMALE; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-2; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; TH1 CELLS; VACCINES, DNA;

EID: 35748970465     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00472-06     Document Type: Article

References (34)

1. Al-Mariri, A., A. Tibor, P. Mertens, X. De Bolle, P. Michel, J. Godefroid, K. Walravens, and J.-J. Letesson. 2001. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect. Immun. 69:4816-4822.
2. Anonymous. 1986. Joint FAO/WHO expert committee on brucellosis. WHO Tech. Rep. Ser. 740:1-132.
3. Blasco, J. 1990. Brucella ovis, p. 352-378. In K. Nielson and J. R. Duncan (ed.), Animal brucellosis. CRC Press, Boca Raton, FL.
4. Blasco, J. M., and R. Diaz. 1993. Brucella melitensis Rev-1 vaccine as a cause of human brucellosis. Lancet 342:805.
5. Blasco, J. M., C. M. Marin, M. Barberan, I. Moriyon, and R. Diaz. 1987. Immunization with Brucella melitensis Rev-1 against Brucella ovis infection of rams. Vet. Microbiol. 14:381-392.
6. Bosseray, N., and M. Plommet. 1983. A laboratory reference vaccine to titrate immunogenic activity of antibrucella vaccines in mice. Ann. Rech. Vet. 14:163-168.
7. Bowden, R. A., A. Cloeckaert, M. S. Zygmunt, and G. Dubray. 1995. Outer-membrane protein- and rough lipopolysaccharide-specific monoclonal antibodies protect mice against Brucella ovis. J. Med. Microbiol. 43:344-347.
8. Bowden, R. A., S. M. Estein, M. S. Zygmunt, G. Dubray, and A. Cloeckaert. 2000. Identification of protective outer membrane antigens of Brucella ovis by passive immunization of mice with monoclonal antibodies. Microbes Infect. 2:481-488.
9. Carpenter, T. E., S. L. Berry, and J. S. Glenn. 1987. Economics of Brucella ovis control in sheep: epidemiologic simulation model. J. Am. Vet. Med. Assoc. 190:977-982.
10. + T helper 1 response that protects against Brucella melitensis infection. Infect. Immun. 73:8079-8088.
11. Cassataro, J., K. Pasquevich, L. Bruno, J. C. Wallach, C. A. Fossati, and P. C. Baldi. 2004. Antibody reactivity to Omp31 from Brucella melitensis in human and animal infections by smooth and rough Brucellae. Clin. Diagn. Lab. Immunol. 11:111-114.
12. Cassataro, J., C. A. Velikovsky, S. de la Barrera, S. M. Estein, L. Bruno, R. Bowden, K. A. Pasquevich, C. A. Fossati, and G. H. Giambartolomei. 2005. A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response. Infect. Immun. 73:6537-6546.
13. Cespedes, S., E. Andrews, H. Folch, and A. Onate. 2000. Identification and partial characterisation of a new protective antigen of Brucella abortus. J. Med. Microbiol. 49:165-170.
14. de la Barrera, S., M. Aleman, R. Musella, P. Schierloh, V. Pasquinelli, V. Garcia, E. Abbate, and C. Sasiain Mdel. 2004. IL-10 down-regulates costimulatory molecules on Mycobacterium tuberculosis-pulsed macrophages and impairs the lytic activity of CD4 and CD8 CTL in tuberculosis patients. Clin. Exp. Immunol. 138:128-138.
15. Estein, S. M., J. Cassataro, N. Vizcaino, M. S. Zygmunt, A. Cloeckaert, and R. A. Bowden. 2003. The recombinant Omp31 from Brucella melitensis alone or associated with rough lipopolysaccharide induces protection against Brucella ovis infection in BALB/c mice. Microbes Infect. 5:85-93.
16. Fernandes, D. M., and C. L. Baldwin. 1995. Interleukin-10 downregulates protective immunity to Brucella abortus. Infect. Immun. 63:1130-1133.
17. Gradwell, D. V., and F. E. Van Zyl. 1975. Effectivity of Rev 1 vaccine in rams against Brucella ovis infection. J. S. Afr. Vet. Assoc. 46:349-351.
18. Guilloteau, L. A., K. Laroucau, N. Vizcaino, I. Jacques, and G. Dubray. 1999. Immunogenicity of recombinant Escherichia coli expressing the omp31 gene of Brucella melitensis in BALB/c mice. Vaccine 17:353-361.
19. Gurunathan, S., C. Y. Wu, B. L. Freidag, and R. A. Seder. 2000. DNA vaccines: a key for inducing long-term cellular immunity. Curr. Opin. Immunol. 12:442-447.
20. Jiménez de Bagüés, M. P., P. H. Elzer, J. M. Blasco, C. M. Marín, C. Gamazo, and A. J. Winter. 1994. Protective immunity to Brucella ovis in BALB/c mice following recovery from primary infection or immunization with subcellular vaccines. Infect. Immun. 62:632-638.
21. Jiménez de Bagüés, M. P., A. Terraza, A. Gross, and J. Dornand. 2004. Different responses of macrophages to smooth and rough Brucella spp.: relationship to virulence. Infect. Immun. 72:2429-2433.
22. Ko, J., and G. A. Splitter. 2003. Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans. Clin. Microbiol. Rev. 16:65-78.
23. Marín, C. M., M. Barberan, M. P. Jimenez de Bagues, and J. M. Blasco. 1990. Comparison of subcutaneous and conjunctival routes of Rev 1 vaccination for the prophylaxis of Brucella ovis infection in rams. Res. Vet. Sci. 48:209-215.
24. Murphy, E. A., J. Sathiyaseelan, M. A. Parent, B. Zou, and C. L. Baldwin. 2001. Interferon-gamma is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c mice. Immunology 103:511-518.
25. Oliveira, S. C., and G. A. Splitter. 1996. Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine 14:959-962.
26. Ramsay, A. J., S. J. Kent, R. A. Strugnell, A. Suhrbier, S. A. Thomson, and I. A. Ramshaw. 1999. Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity. Immunol. Rev. 171:27-44.
27. Ramshaw, I. A., and A. J. Ramsay. 2000. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today 21:163-165.
28. Stober, C. B., U. G. Lange, M. T. Roberts, A. Alcami, and J. M. Blackwell. 2005. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. J. Immunol. 175:2517-2524.
29. Tabatabai, L. B., and G. W. Pugh, Jr. 1994. Modulation of immune responses in Balb/c mice vaccinated with Brucella abortus Cu-Zn superoxide dismutase synthetic peptide vaccine. Vaccine 12:919-924.
30. Trujillo, I. Z., A. N. Zavala, J. G. Caceres, and C. Q. Miranda. 1994. Brucellosis. Infect. Dis. Clin. N. Am. 8:225-241.
31. Velikovsky, C. A., F. A. Goldbaum, J. Cassataro, S. Estein, R. A. Bowden, L. Bruno, C. A. Fossati, and G. H. Giambartolomei. 2003. Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used. Infect. Immun. 71:5750-5755.
32. Woodland, D. L. 2004. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol. 25:98-104.
33. Yang, X., M. Hudson, N. Walters, R. F. Bargatze, and D. W. Pascual. 2005. Selection of protective epitopes for Brucella melitensis by DNA vaccination. Infect. Immun. 73:7297-7303.
34. Young, E. J. 1995. An overview of human brucellosis. Clin. Infect. Dis. 21:283-290.